Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080279 | 0.94 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2MAPTL3MBTL1ALOX5 | |
| SCHEMBL4080500 | 0.87 | PTGER4 (0.53) | ALDH1A1SMN1; SMN2MAPTL3MBTL1ALOX5 | |
| SCHEMBL5574390 | 0.87 | MAPT (0.42) | ALDH1A1SMN1; SMN2MAPTL3MBTL1ALOX5 | |
| SCHEMBL4077453 | 0.81 | KMT2A (0.42) | ALDH1A1SMN1; SMN2MAPTHTTKMT2A | |
| SCHEMBL4077776 | 0.81 | PTGER4 (0.55) | ALDH1A1SMN1; SMN2MAPTALOX5PTGER4 | |
| SCHEMBL4084927 | 0.79 | PTGER4 (0.42) | ALDH1A1SMN1; SMN2MAPTHTTKMT2A | |
| SCHEMBL5574386 | 0.79 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2MAPTL3MBTL1ALOX5 | |
| SCHEMBL15163216 | 0.78 | PTGER4 (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1PTGER4 | |
| SCHEMBL4087627 | 0.78 | PTGER4 (0.40) | ALDH1A1SMN1; SMN2MAPTHTTKMT2A | |
| SCHEMBL28771821 | 0.77 | KMT2A (0.48) | ALDH1A1MAPTKMT2AMEN1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | ALDH1A1 1638/4885SMN1; SMN2 951/4885MAPT 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.